Health sciences

WinWire launches Vaccine Management Solution Built on Microsoft Azure

Retrieved on: 
Thursday, January 28, 2021
Vaccination, Vaccine, Virology, Medical specialties, Vaccination schedule, Medicine, Medical research, Health sciences

SANTA CLARA, Calif., Jan. 28, 2021 /PRNewswire/ -- WinWire Technologies , a digital engineering services company, launched its Vaccine Management solution built on Azure.

Key Points: 
  • SANTA CLARA, Calif., Jan. 28, 2021 /PRNewswire/ -- WinWire Technologies , a digital engineering services company, launched its Vaccine Management solution built on Azure.
  • The WinWire solution enables them to efficiently develop and manage vaccine programs at scale, speeding up vaccine delivery.
  • Vaccine management solution supports the public health administrators, healthcare providers, and care communities to expedite vaccine dissemination.
  • "Our vaccine management solution streamlines vaccine administration and management by enabling healthcare providers to alleviate the complexity associated with vaccine administration and help businesses to reopen and bring employees back to offices safely."

TGOD Launches Stillwater Brands' RIPPLE Gummies in Canada

Retrieved on: 
Thursday, January 28, 2021
Medicinal plants, Psychoactive drugs, Cannabis smoking, Herbalism, Entheogens, Euphoriants, Payment systems, Health sciences, Cannabis, Effects of cannabis, Gummy candy, Medical cannabis

RIPPLE Gummies are made using certified organically grown cannabis, real fruit juice and all-natural flavours and colours.

Key Points: 
  • RIPPLE Gummies are made using certified organically grown cannabis, real fruit juice and all-natural flavours and colours.
  • RIPPLE Gummies leveragethe samefast-acting proprietary technology used in quick-dissolving RIPPLE powder, which rapidly became one of the top-selling SKUs within the cannabis beverage category due to its scientifically validated 15-minute onset, a first in Canada.
  • "RIPPLE Gummies offer another convenient option for Canadians to consume their desired dose of cannabinoids with a unique, predictable onset of action."
  • As part of its licensing agreement with Stillwater, TGOD plans to further expand its RIPPLE offering with additional flavours Honey Infusion CBD and Mango Balance, scheduled to launch in the second quarter of 2021.

DGAP-News: Sernova Announces Collaboration Agreements with Multiple Pharmaceutical Industry Leaders

Retrieved on: 
Thursday, January 28, 2021
Health sciences, Life sciences, Branches of biology, Biotechnology, Cell biology, Cell therapy, Therapy, Pharmaceutical industry

LONDON, ONTARIO - January 28, 2021 - Sernova Corp. (TSX-V: SVA)(OTCQB: SEOVF)(FSE: PSH), a leading clinical-stage regenerative medicine therapeutics company, announced today that it has entered into multiple research collaboration agreements with global pharmaceutical companies.

Key Points: 
  • LONDON, ONTARIO - January 28, 2021 - Sernova Corp. (TSX-V: SVA)(OTCQB: SEOVF)(FSE: PSH), a leading clinical-stage regenerative medicine therapeutics company, announced today that it has entered into multiple research collaboration agreements with global pharmaceutical companies.
  • Sernova is deploying its in-house cell therapy expertise and patent-protected Cell Pouch technologies in combination with proprietary therapeutic cell assets designated by the pharmaceutical collaborators.
  • Further details of these agreements will be kept confidential for strategic reasons.
  • Sernova's goal is to provide people with a functional cure for multiple chronic and rare diseases."

Why Portland, OR Dispensaries like Jayne PDX Are Designated Essential Businesses

Retrieved on: 
Thursday, January 28, 2021
Cannabis in the United States, Cannabis dispensaries in the United States, Cannabis, Dispensary, Health sciences, Health, Pharmaceutical sciences

Hundreds of businesses have had to close or drastically change their habits in order to keep going.

Key Points: 
  • Hundreds of businesses have had to close or drastically change their habits in order to keep going.
  • Jayne has taken several steps to handle COVID and work past it to help the customers who need cannabis the most.
  • Jayne is outfitted with new plexiglass screens to keep the proper health barrier between staff and customers.
  • In the midst of uncertainty, Jayne PDX and other cannabis dispensaries have continued to thrive and give back to the community.

Covid-T™ Clinical Development Program Initiated Regulatory Advisory Group Engaged

Retrieved on: 
Thursday, January 28, 2021
Health sciences, Health, Medicine, Medical research, Pharmacy, Coronavirus disease, Occupational safety and health, Zoonoses, COVID-19 vaccine, Food and Drug Administration, Pharmaceutical industry, Vaccine

VANCOUVER, BC, Jan. 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF)("BioVaxys" or "Company") is pleased to announce that it has initiated the clinical development program for Covid-T, the Company's novel diagnostic platform for detecting T-cell activity.

Key Points: 
  • VANCOUVER, BC, Jan. 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF)("BioVaxys" or "Company") is pleased to announce that it has initiated the clinical development program for Covid-T, the Company's novel diagnostic platform for detecting T-cell activity.
  • Covid-T also provides an ability to evaluate the effectiveness of any SARS-CoV-2 vaccine candidate in stimulating T-cell immunity.
  • BioVaxys has prepared the clinical development plan for Covid-T, and engaged global regulatory advisory group Rio Pharmaceutical Services ("RPS") of Bridgewater, NJ, to provide strategic regulatory guidance, prepare an FDA pre-submission guidance package, recommend regulatory pathway, and support BioVaxys on the registration filing.
  • RPS has provided pharmaceutical and medical-device advisory services across the entire drug, biologic and device development and approval spectrum of the pharmaceutical industry since 2000.

Gage Cannabis Announces Final Closing of Oversubscribed Regulation A+ Equity Financing

Retrieved on: 
Thursday, January 28, 2021
Medicinal plants, Herbalism, Entheogens, Euphoriants, Health sciences, Branches of biology, Pharmaceutical sciences, Medical cannabis, Cannabis

DETROIT, Jan. 28, 2021 /PRNewswire/ -- Gage Growth Corp. ("Gage" or the "Company"), the leading high-quality craft cannabis brand in Michigan, has announced the final closing of its Regulation A, Tier 2, equity financing (the "Offering").

Key Points: 
  • DETROIT, Jan. 28, 2021 /PRNewswire/ -- Gage Growth Corp. ("Gage" or the "Company"), the leading high-quality craft cannabis brand in Michigan, has announced the final closing of its Regulation A, Tier 2, equity financing (the "Offering").
  • In total, Gage issued 28,571,400 Subordinate Voting Shares for gross proceeds of US$50,000,000, the maximum amount qualified under the Company's offering circular (see Gage Cannabis Co. Offering Circular ).
  • "We are humbled and excited by the significant interest and investor demand we received for our oversubscribed Reg A financing," said Fabian Monaco, President of Gage.
  • Gage Growth Corp. is innovating and curating the highest quality cannabis experiences possible for cannabis consumers in the state of Michigan and bringing internationally renowned brands to market.

Toothpaste & Mouthwash to Account for Two-third Sales in Oral Hygiene Products Market: Persistence Market Research Study

Retrieved on: 
Thursday, January 28, 2021
Mouth, Oral hygiene, Hygiene, Health sciences, Toothpaste, Dentistry

Increasing prevalence of these conditions across the world is expected to boost demand in the global oral hygiene products market .

Key Points: 
  • Increasing prevalence of these conditions across the world is expected to boost demand in the global oral hygiene products market .
  • Several initiatives for oral health awareness are being undertaken by leading oral hygiene market players.
  • The toothpaste segment, under product, is expected to hold more than one-third revenue share in the global oral hygiene products market.
  • Low capital cost required for manufacturing oral hygiene products will result in increasing number of market players in future,"says a Persistence Market Research analyst.

Covid-T™ Clinical Development Program Initiated Regulatory Advisory Group Engaged

Retrieved on: 
Thursday, January 28, 2021
Health sciences, Health, Medicine, Medical research, Pharmacy, Coronavirus disease, Occupational safety and health, Zoonoses, COVID-19 vaccine, Food and Drug Administration, Pharmaceutical industry, Vaccine

VANCOUVER, BC, Jan. 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF)("BioVaxys" or "Company") is pleased to announce that it has initiated the clinical development program for Covid-T, the Company's novel diagnostic platform for detecting T-cell activity.

Key Points: 
  • VANCOUVER, BC, Jan. 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF)("BioVaxys" or "Company") is pleased to announce that it has initiated the clinical development program for Covid-T, the Company's novel diagnostic platform for detecting T-cell activity.
  • Covid-T also provides an ability to evaluate the effectiveness of any SARS-CoV-2 vaccine candidate in stimulating T-cell immunity.
  • BioVaxys has prepared the clinical development plan for Covid-T, and engaged global regulatory advisory group Rio Pharmaceutical Services ("RPS") of Bridgewater, NJ, to provide strategic regulatory guidance, prepare an FDA pre-submission guidance package, recommend regulatory pathway, and support BioVaxys on the registration filing.
  • RPS has provided pharmaceutical and medical-device advisory services across the entire drug, biologic and device development and approval spectrum of the pharmaceutical industry since 2000.

Government Database Shows 7,844 Injuries and 181 Deaths Following COVID Vaccine as of Jan. 15 says Children's Health Defense

Retrieved on: 
Thursday, January 28, 2021
Medical research, Health sciences, Medicine, Articles, BioNTech, Pfizer, BioNTech, Clinical trials, COVID-19 vaccine, Pfizer-BioNTech COVID-19 vaccine, COVID-19 vaccination campaign in Italy

According to Reuters, 10,595,866 individuals have received one or more COVID-19 vaccines as of January 15.

Key Points: 
  • According to Reuters, 10,595,866 individuals have received one or more COVID-19 vaccines as of January 15.
  • Miami obstetrician Dr. Gregory Michael suffered from a hemorrhagic stroke after receiving Pfizer/BioNtech's COVID vaccine.
  • Data about deaths following receipt of the experimental Pfizer/BioNTech shot are also emerging from Israel , Norway , Portugal , Sweden , and Switzerland .
  • CHD also asks for full transparency in post-marketing data that reports all health outcomes (including new diagnoses of autoimmune disorders), adverse events and deaths from COVID-19 vaccine.

ATI Physical Therapy Names John Sanford Vice President of Design, Construction and Facilities

Retrieved on: 
Thursday, January 28, 2021
Medical specialties, Health sciences, Health care, Rehabilitation medicine, Sports medicine, ATI Physical Therapy, Bolingbrook, Illinois, Physical therapy, Fabless semiconductor companies, Ati, ATI Technologies, Therapy

BOLINGBROOK, Ill., Jan. 28, 2021 /PRNewswire/ --ATI Physical Therapy (ATI), one of the nation's largest providers of physical therapy services, today announced the hiring of John Sanford as Vice President of Design, Construction and Facilities.

Key Points: 
  • BOLINGBROOK, Ill., Jan. 28, 2021 /PRNewswire/ --ATI Physical Therapy (ATI), one of the nation's largest providers of physical therapy services, today announced the hiring of John Sanford as Vice President of Design, Construction and Facilities.
  • He will report to Todd Powers, Senior Vice President of Real Estate.
  • An experienced design and construction professional with a background in architecture, Sanford is skillful in developing and transforming design ideas into high-quality spatial and aesthetic experiences in the commercial retail space.
  • "His program management expertise and eye toward efficiency at every step of the construction process will be of great value to our development efforts.